A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: Clinical efficacy and side effects

The Journal of Allergy and Clinical Immunology

Volumn 91, Issue 3, 1993, Pages 709-722

  Haugaard, Lars ^a   Dahl, Ronald ^a   Jacobsen, Lars ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b ALK ABELLÓ   (Denmark)

Author keywords

bronchial asthma; Dose response; houst dust mite allergy; immunotherapy

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CROMOGLYCATE DISODIUM; HISTAMINE; HOUSE DUST ALLERGEN; STEROID;

ADOLESCENT; ADULT; ALLERGIC ASTHMA; ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; FORCED EXPIRATORY VOLUME; HOUSE DUST ALLERGY; HUMAN; IMMUNOTHERAPY; INHALATIONAL DRUG ADMINISTRATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PEAK EXPIRATORY FLOW; PRICK TEST; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SCHOOL CHILD; URTICARIA;

ADOLESCENT; ADULT; ALLERGENS; ANIMALS; ANTIGENS, DERMATOPHAGOIDES; ASTHMA; BRONCHIAL PROVOCATION TESTS; CHILD; DESENSITIZATION, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DOUBLE-BLIND METHOD; DRUG HYPERSENSITIVITY; DRUG TOLERANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; MITES; SKIN TESTS;

EID: 0027467542     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/0091-6749(93)90190-Q     Document Type: Article

References (59)

1. Prophylactic inoculation against hay fever
2. Shortened version of a World Health Organization/ International Union of Immunological Societies Working Group Report
3. Allergen immunotherapy in asthma: evidence for efficacy
4. Immunotherapy position paper Prepared by the Immunotherapy Subcommittee of The European Academy of Allergology and Clinical Immunology
5. Study of the role of antigen dosage in the treatment of pollenosis and pollen asthma
6. Value of hypersensitization therapy for perennial bronchial asthma in children
7. Comparison of two dosages of ragweed extract in the treatment of pollenosis
8. Dose dependence of Hymenoptera venom immunotherapy
9. The management of clinical allergy. Part III. Inhalant allergy therapy
10. A comparative study of the effectiveness of the Rinkel method and the current standard method of immunotherapy for ragweed pollen hay fever
11. Immunotherapy for aeroallergen disease
12. A comparison of immunotherapy schedules for injection treatment of ragweed pollen hay fever
13. Comparative safety and efficacy of short ragweed extracts differing in potency and composition in the treatment of fall hay fever
14. The importance of allergen dose on the safety and efficacy of immunotherapy of ragweed hayfever with standardized short ragweed extracts (SR)
15. Effective hyposensitization in allergic rhinitis using a potent partially purified extract of house dust mite
16. Fatal misadventures
17. Allergen injection immunotherapy (hyposensitization) on trial
18. CSM Update Desensitising vaccines
19. Dust mite allergens and asthma—a worldwide problem
20. Standardization of Dermatophagoides pteronyssinus: assessment of potency and allergen content in ten coded extracts
21. American Thoracic Society: standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma
22. Purification and partial characterization of two major allergens from the house dust mite Dermatophagoides pteronyssinus
23. Prospective study on immunologic changes induced by two different Dermatophagoides pteronyssinus extracts prepared from whole mite culture and mite bodies
24. Immunotherapy with partially purified and standardized animal dander extracts. I. Clinical results from a double-blind study on patients with animal dander asthma
25. Standardization of allergen extracts with appropriate methods
26. Determination of histamine PCP: comparison of linear and logarithmic interpolation
27. Bronchial reactivity to histamine: a method and clinical survey
28. The precision of the conjunctival provocation test
29. Clinical and immunologic evaluation of tyrosine-adsorbed Dermatophagoides pteronyssinus extract: a double-blind placebo-controlled trial
30. Annual fluctuations of mites and fungi in Danish house dust: an example
31. A study of the criteria used for clinical evaluation of prophylactic treatment in bronchial asthma
32. Hyposensitization in mite asthma
33. Hyposensitization with Dermatophagoides pteronyssinus antigen: trial in asthma induced by house dust
34. Hyposensitization with Dermatophagoides pteronyssinus in house dust allergy: a controlled study of clinical and immunological effects
35. A double-blind controlled trial of house mite fortified house dust vaccine in childhood asthma
36. Results of a clinical trial with a Dermatophagoides pteronyssinus adsorbed vaccine
37. Controlled trial of hyposensitization of Dermatophagoides pteronyssinus in children with asthma
38. Immunotherapy with a standardized Dermatophagoides extract. I. In vivo and in vitro parameters after a short course of treatment
39. Specific immunotherapy with a standardized Dermatophagoides pteronyssinus extract. II. Prediction of efficacy of immunotherapy
40. Hyposensitization with house dust mite vaccine in bronchial asthma
41. House dust mite hyposensitization
42. A trial of house dust mite extract in bronchial asthma
43. Hyposensitization in asthmatics with mPEG-modified and unmodified house dust mite extract. II. Effect evaluated by challenges with allergen and histamine
44. Hyposensitization in asthmatics with mPEG modified and unmodified house dust mite extract. I. Clinical effect evaluated by diary cards and a retrospective assessment
45. Non-allergic bronchial hyperreactivity in asthmatic children decreases with age and increases with mite immunotherapy
46. A controlled study of immunotherapy with Pharmalgen D. farinae mite extract
47. Immunotherapy in patients allergic to cat and dog dander. I. Clinical results
48. Immunotherapy in allergy to dog: a double-blind clinical study
49. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. III. Systemic reactions during the rush protocol in patients suffering from asthma
50. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. IV. Systemic reactions according to the immunotherapy schedule
51. Hyposensitization in asthmatics with mPEG-modified and unmodified house dust mite extract. IV. Occurrence and prediction of side effects
52. A prospective national study of the safety of immunotherapy
53. Fatalities from immunotherapy (IT) and skin testing (ST)
54. Importance of physician identification of airflow limitation in stable asthmatics
55. Side effects during immunotherapy with purified grass pollen extracts
56. Prospective survey of local and systemic reactions to immunotherapy with pollen extracts
57. Late and immediate systemic-allergic reactions to inhalant allergen immunotherapy
58. Late systemic-allergic reactions to inhalant allergen immunotherapy